Syros Pharmaceuticals

Syros Pharmaceuticals is a company listed under the stock ticker SYRS (US).

Acquisition, funding and merger involving Syros Pharmaceuticals.

• Syros Pharmaceuticals has announced the acquisition of Tyme Technologies  (posted on November 29 2022).
• Syros Pharmaceuticals has just announced a $190 Million fundraising (posted on July 5 2022).
• Syros Pharmaceuticals has announced the acquisition of Tyme Technologies  (posted on July 5 2022).

View the org chart displaying its 17 main executives

Most searched biographies at Syros Pharmaceuticals

• Conley Chee, Chief Executive Officer
• Srinivas Akkaraju, Director
• Nancy Simonian, Director

Popular executive movements at Syros Pharmaceuticals

• Nancy Simonian who is Director, President, Chief Executive Officer and Principal Financial Officer, will become Director on Dec. 2, 2023  (posted on October 3 2023).
• Conley Chee who is Chief Commercial Officer, will be promoted to Chief Executive Officer on Dec. 2, 2023  (posted on October 3 2023).

Create your alert
to follow the executive moves at Syros Pharmaceuticals.

Syros Pharmaceuticals has 1,860 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• MedMen has filed for bankruptcy protection  (posted on April 28 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma
• Emma Walmsley - Chief Executive Officer and Director at GSK

Learn more about the Pharmaceuticals industry >

Press releases by Syros Pharmaceuticals

• Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression :: Syros Pharmaceuticals, Inc. (SYRS)
• Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) :: Syros Pharmaceuticals, Inc. (SYRS)
• Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial :: Syros Pharmaceuticals, Inc. (SYRS)
• Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update :: Syros Pharmaceuticals, Inc. (SYRS)
• Press Releases :: Syros Pharmaceuticals, Inc. (SYRS)
• Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 :: Syros Pharmaceuticals, Inc. (SYRS)
• Syros to Participate in TD Cowen 44th Annual Health Care Conference :: Syros Pharmaceuticals, Inc. (SYRS)
• Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene :: Syros Pharmaceuticals, Inc. (SYRS)
• Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants :: Syros Pharmaceuticals, Inc. (SYRS)
• Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine :: Syros Pharmaceuticals, Inc. (SYRS)
• View more press releases Close

Social media about Syros Pharmaceuticals

• Syros Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Syros Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Conley Chee

Call Syros Pharmaceuticals at +1 617...

View the org chart

Register to receive your alert

Report an error